Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Concetta Conticello

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Diseases (Basel, Switzerland)|February 26, 2026
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian CentersVittorio Del Fabro, Lara Gullo, Giuliana Giunta, et al.
Cancer|September 2, 2023
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditionsAndrea Duminuco, Antonella Nardo, Alessandra Orofino, et al.
Leukemia Research Reports|November 18, 2020
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable costGiuseppe Milone, Concetta Conticello, Salvatore Leotta, et al.
Cancers|July 26, 2020
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma CellsCesarina Giallongo, Daniele Tibullo, Fabrizio Puglisi, et al.
Cancers|April 14, 2026
FcγRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune DysfunctionDaniela Cambria, Maria Teresa Cannizzaro, Nunziatina Laura Parrinello, et al.
Chemotherapy|September 19, 2019
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of ChemotherapySalvatore Leotta, Maria Cristina Pirosa, Uros Markovic, et al.
Journal of Clinical Medicine|July 12, 2025
COVID-19 Vaccine Experience: Loss of Humoral Response Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients and Positive Effect of Booster DoseUros Markovic, Elvira Scalisi, Giuliana Giunta, et al.
Scientific Reports|November 26, 2024
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysisElisa Gelli, Claudia Martinuzzi, Debora Soncini, et al.
International Journal of Molecular Sciences|June 23, 2020
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3Fabrizio Puglisi, Nunziatina Laura Parrinello, Cesarina Giallongo, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Diseases (Basel, Switzerland)|February 26, 2026
Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian CentersVittorio Del Fabro, Lara Gullo, Giuliana Giunta, et al.
Cancer|September 2, 2023
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditionsAndrea Duminuco, Antonella Nardo, Alessandra Orofino, et al.
Leukemia Research Reports|November 18, 2020
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable costGiuseppe Milone, Concetta Conticello, Salvatore Leotta, et al.
Cancers|July 26, 2020
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma CellsCesarina Giallongo, Daniele Tibullo, Fabrizio Puglisi, et al.
Cancers|April 14, 2026
FcγRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune DysfunctionDaniela Cambria, Maria Teresa Cannizzaro, Nunziatina Laura Parrinello, et al.
Chemotherapy|September 19, 2019
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of ChemotherapySalvatore Leotta, Maria Cristina Pirosa, Uros Markovic, et al.
Journal of Clinical Medicine|July 12, 2025
COVID-19 Vaccine Experience: Loss of Humoral Response Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients and Positive Effect of Booster DoseUros Markovic, Elvira Scalisi, Giuliana Giunta, et al.
Scientific Reports|November 26, 2024
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysisElisa Gelli, Claudia Martinuzzi, Debora Soncini, et al.
International Journal of Molecular Sciences|June 23, 2020
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3Fabrizio Puglisi, Nunziatina Laura Parrinello, Cesarina Giallongo, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Pageof 10